First Mercantile Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

First Mercantile Trust’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$85K	Sell	3,066 -235	-7%	-$6.71K	0.01%	706
2021 Q2	$98K	Sell	3,301 -406	-11%	-$11.7K	0.01%	694
2021 Q1	$104K	Sell	3,707 -497	-12%	-$13.7K	0.01%	672
2020 Q4	$119K	Sell	4,204 -177	-4%	-$4.58K	0.01%	636
2020 Q3	$121K	Buy	4,381 +325	+8%	+$8.52K	0.01%	615
2020 Q2	$99K	Buy	+4,056	New	+$80.1K	0.01%	670

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First Mercantile Trust's RVNC Position: Q3 2021 in Review

First Mercantile Trust reduced its Revance Therapeutics, Inc. (RVNC) stake by 7.1% in Q3 2021, selling an estimated $6.71K and leaving 3,066 shares worth $85K. The position accounts for 0.01% of the portfolio, ranked #706.

First Mercantile Trust first reported a position in RVNC in Q2 2020 and has held it in 6 quarters since. The position peaked at $121K in Q3 2020. 158 funds tracked by Wall St. Rank hold RVNC as of Q3 2021.

First Mercantile Trust held 3,066 shares of Revance Therapeutics, Inc. worth $85K as of Q3 2021.
First Mercantile Trust sold 235 Revance Therapeutics, Inc. shares in Q3 2021, an estimated $6.71K.
Revance Therapeutics, Inc. made up 0.01% of First Mercantile Trust's portfolio in Q3 2021, its #706 holding.
First Mercantile Trust first reported a position in Revance Therapeutics, Inc. in Q2 2020 and has held it in 6 quarters since.
First Mercantile Trust's Revance Therapeutics, Inc. position peaked at $121K in Q3 2020.
158 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2021.

Based on First Mercantile Trust's 13F filing for Q3 2021, filed 24 Nov 2021.